Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus

Cerebellum

Volumn 15, Issue 1, 2016, Pages 38-42

  Feil, Katharina ^a   Bremova, Tatiana ^a,b   Muth, Carolin ^a   Schniepp, Roman ^a   Teufel, Julian ^a   Strupp, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

4 Aminopyridine; Acetyl DL leucine; Chlorzoxazone; Downbeat nystagmus; Episodic ataxia type 2; Niemann Pick type C

Indexed keywords

4 AMINOPYRIDINE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CHLORZOXAZONE; FAMPRIDINE; N ACETYLLEUCINE ETHANOLAMINE; PLACEBO; ACETYLLEUCINE; CENTRAL MUSCLE RELAXANT; LEUCINE; POTASSIUM CHANNEL BLOCKING AGENT;

ATAXIA; BODY POSTURE; CEREBELLAR ATAXIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPISODIC ATAXIA TYPE 2; EYE MOVEMENT; GAIT DISORDER; HUMAN; MEDICATION THERAPY MANAGEMENT; MOTOR PERFORMANCE; NERVE CONDUCTION; NEUROPROTECTION; NONHUMAN; NYSTAGMUS; PRIORITY JOURNAL; PURKINJE CELL; REVIEW; SUSTAINED DRUG RELEASE; ANALOGS AND DERIVATIVES; COMPLICATION; NYSTAGMUS, PATHOLOGIC; PROCEDURES; TRENDS;

4-AMINOPYRIDINE; CEREBELLAR ATAXIA; CHLORZOXAZONE; DRUG THERAPY; HUMANS; LEUCINE; MUSCLE RELAXANTS, CENTRAL; NYSTAGMUS, PATHOLOGIC; POTASSIUM CHANNEL BLOCKERS;

EID: 84955718594     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-015-0733-1     Document Type: Review

References (31)

1. Ilg W et al. Consensus paper: management of degenerative cerebellar disorders. Cerebellum. 2014;13(2):248–68.
2. Strupp M et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology. 2003;61(2):165–70.
3. Kalla R et al. 4-aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain. Neurology. 2004;62(7):1228–9.
4. Claassen J, T.J., Kalla R, Spiegel R, Strupp M. Effects of dalfampridine on attacks in patients with episodic ataxia type 2—an observational study. J Neurol, 2012 (in press).
5. Schniepp R et al. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation. J Neurol. 2011;258(9):1708–11.
6. Schniepp R et al. 4-Aminopyridine and cerebellar gait: a retrospective case series. J Neurol. 2012;259(11):2491–3.
7. Strupp M et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology. 2011;77(3):269–75.
8. Strupp M et al. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology. 2004;62(9):1623–5.
9. Alvina K, Khodakhah K. KCa channels as therapeutic targets in episodic ataxia type-2. J Neurosci. 2010;30(21):7249–57.
10. Feil K et al. Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot trial. Neurology. 2013;81(13):1152–8.
11. Strupp M et al. Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J Neurol. 2013;260(10):2556–61.
12. Etzion Y, Grossman Y. Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells. Exp Brain Res. 2001;139(4):419–25.
13. Hille B. Ionic channels of excitable membranes. 3dth ed. Sunderlang: Sinauer; 2001.
14. Alvina K, Khodakhah K. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci. 2010;30(21):7258–68.
15. Weisz CJ et al. Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering. J Neurosci. 2005;25(16):4141–5.
16. Bense S et al. 18F-fluorodeoxyglucose hypometabolism in cerebellar tonsil and flocculus in downbeat nystagmus. Neuroreport. 2006;17(6):599–603.
17. Hourez R et al. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci. 2011;31(33):11795–807.
18. Jen JC. Hereditary episodic ataxias. Ann N Y Acad Sci. 2008;1142:250–3.
19. Claassen J et al. Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study. J Neurol. 2013;260(2):668–9.
20. Baloh RW, Spooner JW. Downbeat nystagmus: a type of central vestibular nystagmus. Neurology. 1981;31(3):304–10.
21. Kalla R et al. Detection of floccular hypometabolism in downbeat nystagmus by fMRI. Neurology. 2006;66(2):281–3.
22. Kalla R et al. 4-Aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain. 2007;130(Pt 9):2441–51.
23. Judge SI, Bever Jr CT. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006;111(1):224–59.
24. Kalla R et al. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus. J Neuroophthalmol. 2011;31(4):320–5.
25. Claassen J et al. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus—effects on slow phase eye velocity, postural stability, locomotion and symptoms. J Neurol Neurosurg Psychiatry. 2013;84(12):1392–9.
26. Claassen J et al. Dalfampridine in patients with downbeat nystagmus—an observational study. J Neurol. 2013;260(8):1992–6.
27. Kremmyda O et al. 4-Aminopyridine suppresses positional nystagmus caused by cerebellar vermis lesion. J Neurol. 2013;260(1):321–3.
28. Schniepp R et al. Increased gait variability is associated with the history of falls in patients with cerebellar ataxia. J Neurol. 2014;261(1):213–23.
29. Giordano I et al. Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia. J Neurol. 2013;260(8):2175–6.
30. Becker-Bense S, F.R., Xiong G, Feil K, Bartenstein P, Strupp M, Dieterich M. Effects of acetyl-DLleucine on the cerebral activation pattern in cerebellar ataxia (FDG-PET study) - Oral Sessions No. O1201. Eur J Neurol. 2015; 22:21–117.
31. Bremova T, M.V., Amraoui Y, Mengel E, Reinke J, Kolníková M, Strupp M. Acetyl-DL-leucine in Niemann-Pick type C: a case series. Neurology. Neurology, 2015. In press.